Status:
TERMINATED
Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer
Lead Sponsor:
CR-CSSS Champlain-Charles-Le Moyne
Conditions:
Prostate Cancer
Eligibility:
MALE
18-85 years
Phase:
PHASE3
Brief Summary
Phase III study that aims to evaluate the necessity of prophylactic antibiotics use after HDR brachytherapy in the treatment of prostate adenocarcinomas.
Detailed Description
INTRODUCTION: High dose rate (HDR) brachytherapy boost with external beam is the current recommended treatment for intermediate and high risk prostate cancers (1, 2). HDR brachytherapy uses transperi...
Eligibility Criteria
Inclusion
- All patients eligible to brachytherapy for the treatment of prostate cancer
- No history of serious urinary tract infection post prostate biopsy
Exclusion
- Urosepsis post biopsy
- Contraindication to brachytherapy
Key Trial Info
Start Date :
February 10 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2023
Estimated Enrollment :
158 Patients enrolled
Trial Details
Trial ID
NCT03862170
Start Date
February 10 2015
End Date
February 1 2023
Last Update
February 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Charles LeMoyne
Greenfield Park, Quebec, Canada, J4V 2H1